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Background: Laboratory testing is one of the fastest growing areas of health services spending in Canada. We
examine the extent to which increases in laboratory expenditures might be explained by testing that is consistent
with guidelines for the management of chronic conditions, by analyzing fee-for-service physician payment data in
British Columbia from 1996/97 and 2005/06.
Method: We used direct standardization to quantify the effect on laboratory expenditures from changes in: fee
levels; population growth; population aging; treatment prevalence; expenditure on recommended tests for those
conditions; and expenditure on other tests. The chronic conditions selected were those with guidelines containing
laboratory recommendations developed by the BC Guidelines and Protocol Advisory Committee: diabetes,
hypertension, congestive heart failure, renal failure, liver disease, rheumatoid arthritis, osteoarthritis and dementia.
Result: Laboratory service expenditures increased by $98 million in 2005/06 compared to 1996/97, or 3.6% per year
after controlling for population growth and aging. Testing consistent with guideline-recommended care for chronic
conditions explained one-third (1.2% per year) of this growth. Changes in treatment prevalence were just as
important, contributing 1.5% per year. Hypertension was the most common condition, but renal failure and
dementia showed the largest changes in prevalence over time. Changes in other laboratory expenditure including
for those without chronic conditions accounted for the remaining 0.9% growth per year.
Conclusion: Increases in treatment prevalence were the largest driver of laboratory cost increases between 1996/97
and 2005/06. There are several possible contributors to increasing treatment prevalence, all of which can be
expected to continue to put pressure on health care expenditures.
Keywords: Clinical Laboratory Techniques/utilization, Clinical Laboratory Techniques/statistics & numerical data,
Guideline care, Diagnostic Techniques and Procedures/economics, Diagnostic Techniques and Procedures/trends,
Fee-for-Service Plans/trends, Health Expenditures/trends, Physician's Practice Patterns/trends, Chronic Disease/
Condition, British Columbia, CanadaBackground
Canadians are concerned about the rising cost of health
care and particularly about whether the public model is
“sustainable” in the face of these cost pressures [1].
Health care was identified as the topic of highest priority
for Canadian voters during the 2011 Federal election, as
it has been in previous elections [2]. Within the overall
landscape of increasing health care costs, expenditures* Correspondence: ssivananthan@chspr.ubc.ca
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distribution, and reproduction in any mediumfor physician/specialists services in Canada have risen
sharply over the past five years, regaining a position as
the second largest cost component (exceeded only by
acute hospital costs) [3]. Payments for laboratory ser-
vices, especially for services provided to seniors, have
seen particularly rapid increases in British Columbia [4].
The question this raises is what the causes are of la-
boratory spending increases. Administrative data cannot
easily answer the question of health impact associated
with this increase in laboratory spending, but it can be
used to help diagnose the sources of cost pressure. Re-
peat testing and technological innovations are likelyntral Ltd. This is an Open Access article distributed under the terms of the
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increases [5-7]. Spending of health care dollars on
chronic conditions and the tests associated both with
diagnosing and managing those conditions may, on the
other hand, help explain the upward trend.
More than half of the Canadian population has at least
one chronic condition, and this rises to 81% of
community-dwelling seniors [8]. Previous studies have
demonstrated that high users of health care services
tend to be individuals with (often multiple) chronic con-
ditions [9]. In British Columbia, as in many other pro-
vinces, there are guidelines associated with the
management of chronic conditions designed to assist
physicians in providing consistent, evidence-based care
[10]. This includes recommendations for specific labora-
tory tests to diagnose and/or manage such conditions. It
should be noted, the study intent is not an evaluation of
adherence to guidelines. Instead, the guidelines are used
simply to indicate the consensus on recommended la-
boratory testing for different chronic conditions. This
paper addresses the question: to what extent can
increases in laboratory expenditures be explained by
testing that is consistent with guidelines for the manage-
ment of chronic conditions?
Building on previous research, our analyses focus on
British Columbia, as no national database exists to allow
a more wide-ranging analysis. Our period of analysis is
1996/97 to 2005/06. We describe the extent to which
population growth and aging, changes in chronic disease
prevalence, and guideline-consistent ordering may ex-
plain increased expenditures for laboratory services.
Methods
Study population and data sources
Our analyses are of the entire population of British
Columbia. The data were accessed through Population
Data BC. Data were analyzed at the individual patient
level using unique but study-specific codes that do not
permit personal identification of either patients or physi-
cians. Permission for data access was provided by the
BC Ministry of Health. Ethics approval for this research
was granted by the University of British Columbia Be-
havioural Research Ethics Board.
We accessed the following files: 1) a central demo-
graphics file for 1996/97 and 2005/06 providing informa-
tion on age and sex of individuals and denominator
information for the analyses; and 2) the fee-for-service
payment files for 1995/96-1996/97 and 2004/05-2005/06
as a two year period is required to confirm a diagnosis.
The fee-for-service data include the date of each visit,
total amount paid, a unique study-specific physician
identification number as well as a study-specific patient
identification number, the physician specialty code, the
diagnostic (ICD9) code most responsible for the visit, afee item code which is a code used to identify each ser-
vice provided by a practitioner, and a service code, which
is a grouping of the fee items that indicates the type of
services rendered by a practitioner. We removed the
effects of fee changes over this period by valuing services
provided in all years at the fee levels in effect on April 1,
2005/06, yielding fee-adjusted expenditures [4].
Classifying chronic conditions
The chronic conditions selected for this study were
those for which specific guidelines developed by the BC
Guidelines and Protocol Advisory Committee for the
Medical Services Commission containing laboratory
recommendations which came into place before 2006
[10]. These were diabetes, hypertension, congestive heart
failure, renal failure, liver disease, rheumatoid arthritis,
osteoarthritis and dementia. Cancer was excluded be-
cause the spectrum of diseases encompassed by the term
resulted in patient profiles with more widely varying pat-
terns of use than those with the other chronic condi-
tions. There are other chronic conditions not included
in this analysis that will have associated laboratory tests.
Increases in testing for those conditions will be captured
as general increases, since our research question is fo-
cused on testing related to guidelines.
Chronic conditions were identified using the first 3
digits only of the International Classification of Disease
(ICD-9) diagnosis codes from records of fee-for-service
payments to general physicians, medical specialists and
surgical specialists. Individuals were counted as having a
chronic condition if they had at least two records show-
ing a diagnosis for the same condition over a two-year
period. This approach to determining treatment preva-
lence is consistent with prior research using administra-
tive data to identify individuals with chronic conditions
[8,11,12]. Treatment prevalence is used here to acknow-
ledge the limitations of administrative data in identifying
the prevalence of disease. While administrative data have
been shown to be quite valid in for this purpose [12], we
are only counting people as having disease if they
received services from a physician who recorded relevant
diagnoses on a billing record. Individuals with one rec-
ord showing a diagnosis of a chronic condition were
counted in a ‘potential’ category, as the diagnosis may
have been recorded as something to be ruled out rather
than being definitive. Payments from 1995/96 – 1996/97
were used to identify chronic conditions for the 1996/97
study population, and 2004/05-2005/06 payments
were used to identify chronic conditions for the 2005/06
study population.
We summarized the information on chronic condi-
tions and created five mutually exclusive groups to re-
flect an overall chronic disease profile for each
individual: ‘No Guideline-Related Chronic Condition’,
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Chronic Conditions’. Individuals who had no record of a
chronic condition diagnosis during the two-year period
were classified in the first category. Those who received
only one record showing a diagnosis for one or more
conditions were classified into the “Potential Chronic
Condition” group. Those with two or more records
showing diagnoses for one condition (irrespective of
“potential” conditions) were counted in the “one
Chronic Condition” group, and so on. Individuals in
these profile groups reflect categorization based on the
chronic diseases with guidelines identified earlier, as per
our research question, but may still have other chronic
conditions outside of the scope of the study.
Laboratory testing
Medical laboratory testing in British Columbia is pro-
vided by community-based and hospital-based laborator-
ies. This study included all laboratory tests paid for
through the Medical Services Plan (MSP) of BC., i.e. not
through hospital global budgets. The latter generally in-
clude only inpatient laboratory services, so this was not
a major limitation.
Payments for laboratory testing were identified in the
MSP data using service codes, regardless of the type of
practitioner that billed for the item. A cluster of labora-
tory tests was created for each of the eight chronic con-
ditions examined, based on the test recommendations
made by the BC Guidelines and Protocol Advisory
Committee (see Additional file 1 for details). All other
tests were classified as not attributable to the chronic
conditions we were examining. The primary base fee is
an administrative cost (similar to a pharmacy dispensing
fee) that is applicable under specified criteria to certain
panel tests performed within the same facility. It could
not be allocated to specific laboratory tests but con-
sisted of a large portion of expenditure and therefore
was treated separately. Total payments and payments
for test subsets by chronic condition were then summed
for each person in the study population. Some tests are
associated with more than one chronic condition. Allo-
cating individuals to the mutually exclusive chronic dis-
ease profile groups and summing separately avoided
double-counting.
Analysis
We approached the analysis using the following
expression:











Where Total Lab Exp is the total expenditure on la-
boratory testing in a given year, Nc is the number of
people with chronic conditions, Nnc is the number of
people without guideline-related chronic conditions,
$Testsr is the expenditure on recommended laboratory
tests for chronic conditions and $Testso is the expend-
iture on other laboratory tests. Using this expression we
can see that after controlling for changes in fees, overall
population growth and population aging, changes in la-
boratory expenditures will come from changes in the
number of people with chronic conditions (the treat-
ment prevalence), changes in the expenditure on recom-
mended tests for each person, or changes in per person
expenditure on other tests. We isolate these three com-
ponents in our analyses using direct standardization.
Results
The cost of utilization
Between 1996/97 and 2005/06, real (constant dollar)
health care services expenditures rose by 25.4% (Table 1).
Laboratory service expenditures rose much faster –
$98.0 million, or 58.7%, an average of 5.3% per year.
Accounting for the growth of the BC population during
the study period, per capita laboratory costs increased
from $41.80 in 1996/97 to $60.40 in 2005/06, still an
extraordinary 44.7% growth over the nine years. Aging
of the population contributed 5.3% (about 0.6% per
year), leaving 37.4% of the per capita growth attributable
to changes in prevalence and changes in laboratory test-
ing intensity.
Demography, treatment prevalence and co-morbidities
In examining chronic condition guideline-consistent la-
boratory test expenditures, one factor that may contrib-
ute to overall expenditure growth is any population-level
changes in the treatment prevalence of the identified
conditions. If age-specific prevalence is increasing, then,
laboratory-related expenditures would increase faster
than what we would expect as a result of population
aging alone.
The treatment prevalence increased for seven out of
eight of the chronic diseases examined in this study.
Hypertension was the most common condition, affecting
6.0% of the population in 1996/97 and 9.9% in 2005/06.
However, the most rapid increases in treatment preva-
lence were found for renal failure and dementia –
227.0% and 145.6% increases respectively (Figure 1A) –
albeit on a much smaller starting population than for
hypertension.
Figure 1B then illustrates the rapid change in the pro-
portion of individuals in the different chronic disease
categories between 1996/97 and 2005/06. An increasing
number of individuals were classified as having one or
more chronic conditions in 2005/06. The largest
Table 1 Dynamics of laboratory expenditures in British Columbia, 1996/97 and 2005/06
% Change
1996/97 2005/06 Overall Average annual
Total health care services expenditures (constant $) 1,594,591,397 1,998,842,372 25.4% 2.5%
Per capita health care services expenditures 399 455 14.3% 1.5%
Total lab expenditures (constant $) 166,914,987 264,904,987 58.7% 5.3%
BC Population 3,999,520 4,383,445 9.7% 1.0%
Per capita lab expenditures 41.8 60.4 44.7% 4.2%
% Growth attributable
Growth attributable to change in age structure 5.3% 0.6%
Growth attributable to other changes 37.4% 3.6%
Note: All numbers reflect age-standardization within broad age bands. We used a direct standardization approach, standardizing 1996/97 utilization rates to the
2005/06 population.
Notes for reading Tables 1 & 2: Rows are only additive for "expenditures per capita". For the other terms of the equation, the denominators differ by column
and so it is impossible to add the values.
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age categories except for the youngest age group of 0–
24 years, was seen for individuals classified as having
three or more chronic conditions.
Intensity of service use
Total expenditures and expenditures per capita
increased over time for all chronic condition groups
(Figure 2A). At both time points, the highest total ex-
penditure was on those without chronic conditions,
while the lowest total expenditure was on individuals
with three or more co-morbidities. In fact, the group
with the biggest percent increase in expenditure between
1996/97 and 2005/06 was also the no guideline-related
chronic condition category.
The intensity of service use, as demonstrated by per
capita costs, tells a more nuanced story. As expected, in-
tensity of service use was higher among those with
chronic conditions, and increased both with the number
of co-morbidities and over time (Figure 2B). The pattern
of care for individuals classified as having three or more
chronic conditions is of particular note because this cat-
egory had the most rapid change in expenditure over the
period.
Chronic condition guideline-consistent laboratory
expenditures
Total expenditures for chronic condition guideline-
consistent laboratory tests increased from $9.9 million
to $28.6 million, a 188.2% change (Table 2). Total expen-
ditures for all other laboratory tests increased from
$138.0 million to $207.5 million, a still substantial but
much smaller 50.3% increase. So while guideline-
consistent laboratory tests showed a much steeper in-
crease over time, the other laboratory tests continued to
represent the more significant share of total expenditure,
even at the end of the period. The 75–84 age group hadthe highest per capita expenditure for guideline-
consistent laboratory tests as well as per capita expendi-
tures for other laboratory tests.
Summing up the effects
As shown in Table 1, 37.4% (3.6% average annual in-
crease) of growth in laboratory expenditures between
1996/9/7 and 2005/06 was attributable to changes other
than aging and population growth. Of this, 13.9% (1.5%
per year) was due to changes in treatment prevalence.
Disaggregating the remaining 20.7% (2.1%) further,
chronic condition guideline-consistent laboratory tests
accounted for 11.3% (1.2%) of the growth and changes
in other laboratory tests 8.5% (0.9%).
Discussion
Spending on laboratory testing in BC increased 58.7%
between 1996/97 and 2005/06. Many factors, including
changes in technology, repeat testing and inappropriate
utilization have been proposed as potential factors con-
tributing to the increase in laboratory utilization [7].
One additional explanation for expenditure increases is
increased testing consistent with medical practice guide-
lines for diagnosing and monitoring patients with
chronic conditions. We find that there was, indeed such
an increase between 1996/97 and 2005/06, but that this
explains only about one-third of the total increase, net
of population growth and aging. Changes in treatment
prevalence were equally important, and unexplained
increases in other laboratory tests for people with and
without the specific chronic conditions of interest were
a large contributing factor.
Several changes in the clinical definition and screening
of chronic conditions occurred between 1996/97 and
2005/06. For example, the clinical definition of diabetes
shifted from a fasting plasma glucose level of greater
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Figure 1 a: Change in treatment prevalence of selected chronic conditions between 1996/97 and 2005/06, by age group. b: Change in
proportion of individuals in different chronic disease categories between 1996/97 and 2005/06.
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Figure 2 a: Total laboratory expenditure on individuals in different chronic disease categories, age standardized, between 1996/97 and
2005/06. The total laboratory expenditure on individuals with no guideline-related chronic disease, maybe one chronic disease, one, two and
three or more chronic diseases in 1996/97 and 2005/06. b: Per capita laboratory expenditures on individuals in different chronic disease
categories, age standardized, between 1996/97 and 2005/06. The per capita laboratory expenditures on individuals with no guideline-related
chronic disease, maybe one chronic disease, one, two and three or more chronic diseases in 1996/97 and 2005/06.
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(eGFR of ~40 mL/min/1.73 m2 for a 40 year old man)
resulting in referral to a renal team for dialysis assess-
ment, changed to every patient with urine abnormalities
and an eGFR <90 mL/min/1.73 m2 receiving immediateTable 2 Disaggregation of laboratory expenditures in British
19
Total expenditure for guideline-consistent laboratory tests 9,9














0 to 24 0.1 0.2 0.1 64.0% 17.3
25 to 44 0.7 1.5 0.8 106.3% 36.3
45 to 54 2.8 5.8 3.0 109.7% 38.8
55 to 64 6.5 13.6 7.1 108.8% 46.1
65 to 74 9.9 24.0 14.0 141.0% 58.5
75 to 84 10.3 27.8 17.5 170.0% 65.8
85 plus 8.2 20.0 11.9 145.4% 55.0
Growth attributable to other changes (from Table 1)
Growth attributable to changes in prevalence
Growth attributable to changes in utilization
Growth attributable to changes in guideline-consistent laboratory testing
Growth attributable to changes in other laboratory testingfurther assessment and management [15,16]. Similarly,
the recommended screening guidelines for Type 2 dia-
betes shifted to begin at age 41 instead of age 46 [13,14].
There were no major changes in clinical definitions or
screening guidelines for osteoarthritis or rheumatoidColumbia, 1996/07 and 2005/06
% Change
96/97 2005/06 Overall Average annual
29,315 28,615,178 188.2% 12.5%














19.2 1.9 10.9% 1.1 1.3 0.2 16.5%
45.0 8.7 24.0% 3.2 3.8 0.6 20.1%
52.4 13.5 34.9% 5.9 7.6 1.6 27.7%
65.7 19.5 42.3% 9.3 11.8 2.4 26.3%
84.1 25.6 43.7% 12.9 16.7 3.8 29.5%
99.2 33.5 50.9% 14.5 19.4 4.9 33.8%
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prevalence across age groups over time11. These changes
are only two factors that may be driving the increase in
treatment prevalence for these chronic conditions, but
they are surely significant ones. Once people are diag-
nosed with a condition, it should be no surprise that
associated health care, and particularly guideline-
consistent expenditures will follow.
There has also been a trend during this period toward
diagnosing “pre-disease” states as part of screening
guidelines, and a growing demand from patients for tests
of their choosing even if the physician may not consider
them beneficial. As previously mentioned, the first
screen for diabetes is now recommended at earlier ages
regardless of risk factors with a diagnosis of “impaired
fasting glucose” as a “pre-diabetic” state at fasting
plasma glucose levels of 6.1 mmol/L. These individuals
being flagged as “at risk” subsequently require follow up
tests until the disease manifests itself [14]. So recom-
mendations for increased population screening at ever
earlier ages and the lower threshold for these pre-disease
"conditions" that then leads to increased monitoring of
individuals with no disease with testing could be another
driver of the increase in other laboratory tests [14,17,18].
Much has been made of the aging population and its
impact on the healthcare system. However, only 5.3% of
the growth in laboratory expenditure over this period
was actually attributable to a change in the age structure.
More is spent on the elderly and this trend has contin-
ued between 1996/97 to 2005/06. However, the impact
of an increasing treatment prevalence of age-specific
chronic conditions, and particularly of an increasing
age-specific prevalence of patients with multiple co-
morbidities, is far more important.
There are some limitations to this study. The fee-for-
service physician data do not include information on
services paid for through alternative payment arrange-
ments such as salaries, sessional payments, or contrac-
tual arrangements. This does not affect the laboratory
payments, which are all by fee-for-service for patients
outside of acute care, but may affect our classification
of these individuals into the chronic disease categories.
In addition, our analysis of chronic conditions was not
exhaustive, but rather focused only on those conditions
that became the subject of incentive programs for pri-
mary care in BC. The “other” laboratory tests, while
not guideline-recommended for these specific chronic
conditions, may still be appropriate for other condi-
tions. Therefore individuals with other potentially
prevalent chronic conditions that were outside the
scope of the conditions selected for this study would
be classified as ‘no guideline-related chronic condition’,
which limits our interpretation of people in this
category.Conclusion
Laboratory testing is one of the fastest growing areas of
physician service provision. In British Columbia, there
was just under $100 million in “new” laboratory expen-
ditures in 2005/06 compared to a 1996/97 base of $167
million. This amounts to a 5.3% average annual increase
in expenditure, or 3.6% per year after removing the
effects of population growth and aging. Our primary re-
search question was the extent to which diligence – test-
ing consistent with guideline-indicated care – could
explain this increase. The answer is that about one-third
of the increase, or about 1.2% per year, can be attributed
to changes in guideline-consistent test ordering. Surpris-
ingly important are designation – the increased likeli-
hood of being diagnosed with a chronic condition – at
1.5% per year, and drift – the general increase in labora-
tory expenditures, including expenditures for people
without these guideline-related chronic conditions - at
0.9% per year. This suggests that future research might
productively focus on the last of these contributing com-
ponents, with an emphasis on the extent to which the
increase in designation and the general increase in test-
ing affects diagnosis or subsequent treatment.
Additional file
Additional file 1: BC Guidelines and Protocol Advisory Committee
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chronic conditions examined.
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